IAEA Activities on 67Cu, 186Re, 47Sc Theranostic Radionuclides and Radiopharmaceuticals

Jalilian AR 1 , Gizawy MA 2 , Alliot C 3 , Takacs S 4 , Chakarborty S 5 , Rovais MRA 6 Show all authors , Pupillo G 7 , Nagatsu K 8 , Park JH 9 , Khandaker MU 10 , Mikolajczak R 11 , Bilewicz A 12 , Okarvi S 13 , Gagnon K 14 , Al Rayyes AH 15 , Lapi SE 16 , Starovoitova V 1 , Korde A 1 , Osso JA 1

Affiliations 

  • 1 Department of Nuclear Sciences and Applications, International Atomic Energy Agency (IAEA), Vienna International Centre, PO Box 100, 1400, Vienna, Austria
  • 2 Radioisotopes Production Facility (RPF), Second Research Reactor (ETRR-2) and Labeled Compounds Department, Hot Labs Center, Egyptian Atomic Energy Authority, P.O. Box 13759, Cairo, Egypt
  • 3 CRCINA, 8 quai Moncousu, 44007 Nantes cedex 1, France & GIP Arronax, 1 rue Aronnax, 44817 Saint-Herblain cedex, France & GIP ARRONAX, rue Aronnax, CS 10112 - 44817 SAINT-HERBLAIN Cedex, France
  • 4 Institute for Nuclear Research, Bem ter 18/c, 4026Debrecen, Hungary
  • 5 Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai -4000, 085, India
  • 6 Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), P.O. Box 14395-836, Tehran, Iran
  • 7 Istituto Nazionale di Fisica Nucleare, Laboratori Nazionali di Legnaro (INFN-LNL), Viale dell'Università 2, 35020 Legnaro (PD), Italy
  • 8 Dept. of Radiopharmaceuticals Development, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage, 263-8555Chiba, Japan
  • 9 Korea Atomic Energy Research Institute, Jeongeup, Jeonbuk 56212, Korea
  • 10 Department of Physics, University of Malaya, 50603 Kuala Lumpur, Malaysia & Center for Biomedical Physics, Sunway University, 47500 Bandar Sunway, Selangor, Malaysia
  • 11 Radioisotope Centre POLATOM, National Centre for Nuclear Research, Andrzej Soltan 7, 05-400, Otwock, Poland
  • 12 Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195Warsaw, Poland
  • 13 Cyclotron and Radiopharmaceuticals Department. King Faisal Specialist Hospital and Research Centre, Takhasussi Road, P.O. Box 3354, 11211Riyadh, Saudi Arabia
  • 14 Cyclotrons and TRACERcenter, GEMS PET Systems AB, GE Healthcare, Uppsala, Sweden
  • 15 Department of Radioisotope, Atomic Energy Commission of Syria (AECS), P.O. Box 6091, Damascus, Syrian Arab Republic
  • 16 Cyclotron Facility, Division of Advanced Medical Imaging Research, Department of Radiology and Chemistry, University of Alabama at Birmingham, Wallace Tumor Institute 310F, 1824 6th Ave. South, Birmingham, AL35233-3300, United States
Curr Radiopharm, 2021;14(4):306-314.
PMID: 32988359 DOI: 10.2174/1874471013999200928162322

Abstract

Despite interesting properties, the use of 67Cu, 186Re and 47Sc theranostic radionuclides in preclinical studies and clinical trials is curtailed by their limited availability due to a lack of widely established production methods. An IAEA Coordinated Research Project (CRP) was initiated to identify important technical issues related to the production and quality control of these emerging radionuclides and related radiopharmaceuticals, based on the request from IAEA Member States. The international team worked on targetry, separation, quality control and radiopharmaceutical aspects of the radionuclides obtained from research reactors and cyclotrons leading to preparation of a standard recommendations for all Member States. The CRP was initiated in 2016 with fourteen participants from thirteen Member States from four continents. Extraordinary results on the production, quality control and preclinical evaluation of selected radionuclides were reported in this project that was finalized in 2020. The outcomes, outputs and results of this project achieved by participating Member States are described in this minireview.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications